Novartis, CH0012005267

Goldman Sachs raises target for Novartis stock to CHF 113.00

Published on 10/02/2026 at 12:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit USD 14.40 billion in the second quarter of 2026. Novartis stock costs EUR 126.85 on October 2, 2026 after EUR 125.65, plus 0.96 percent.

Draufsicht auf Tabletten, Blisterpacks, Beipackzettel und Stethoskop auf weißem Untergrund — Novartis AG CH0012005267 – Flatlay mit generischen Tabletten, Blister, Beipackzettel und Stethoskop auf Weiß, Illustration mit AI erstellt.

Novartis AG (ISIN CH0012005267) was trading at EUR 126.85 at Lang & Schwarz on October 2, 2026, while Goldman Sachs raised its price target from CHF 110.00 to CHF 113.00 and retained a Sell rating. The analyst update was dated September 30, 2026, according to finanzen.ch.

Goldman target moves to CHF 113

Goldman Sachs analyst James Quigley kept the Sell assessment while moving the target from CHF 110.00 to CHF 113.00. The report said his third-quarter estimates were broadly in line with market consensus, giving the target change a limited valuation signal rather than a fresh earnings forecast.

The target remains below the analyst context cited by finanzen.ch, which reported that the stock traded at CHF 118.70 during the September 30 analysis session. That gap keeps analyst caution visible even after the target increase.

Second-quarter sales grew 3 percent

Novartis reported USD 14.40 billion in net sales for the second quarter of 2026, up 3.00 percent in US dollars and 1.00 percent at constant currencies. Core operating income was flat at USD 5.90 billion, according to the published earnings-call transcript from Eulerpool.

The company reaffirmed full-year 2026 guidance after the quarter. Novartis expects low-single-digit sales growth and a low-single-digit decline in core operating income at constant currencies, while second-half sales growth is expected to reach the mid-single-digit range.

Stock remains below the yearly high

For the primary US-listed context, the NVS quote showed a market capitalization of USD 268.10 billion on October 1, 2026, with a 52-week range of USD 121.57 to USD 170.46. The euro reference price converts into that range, so the market data and the analyst target point to different reference currencies rather than a single comparable price.

EUR 126.85 in trading

Novartis was trading at EUR 126.85 at Lang & Schwarz on October 2, 2026 at 12:46 p.m. CEST, up 0.96 percent versus the prior close of EUR 125.65 on October 1, 2026. The SIX listing uses ticker NOVN, and the company is included in the SMI.

The further course of trading is shown by the continuously updated real-time quote of Novartis stock.